27 results for 'nos:"Abbreviated New Drug Applications (ANDA) - Property Rights"'.
J. Wettre declines to transfer an action to the district of Delaware in claims contending a pharmaceutical company filed applications for a generic version of pirfenidone before related patents expired. A prior, similar lawsuit was fully concluded in Delaware before this complaint was filed, and while the pharmaceutical company is incorporated in Delaware, its principal place of business is in New Jersey.
Court: USDC New Jersey, Judge: Wettre , Filed On: March 5, 2024, Case #: 2:23cv4085, NOS: Abbreviated New Drug Applications (ANDA) - Property Rights, Categories: Patent, Venue
Want access to unlimited case records and advanced research tools? Create your free CasePortal account now. No credit card required to register.
Try CasePortal for Free
J. Biggs grants Pfizer’s motion to seal information that is redacted from an associated amended joint case status report in this patent infringement case against a pharmaceutical competitor. Based on the type of infringement case Pfizer brought, the FDA has to withhold approval of the competitor’s product for 2.5 years while the parties litigate the infringement. As this case was previously transferred to a related multidistrict litigation action and the status report was originally confidential, Pfizer correctly argues that it should remain so.
Court: USDC Middle District of North Carolina, Judge: Biggs, Filed On: January 23, 2024, Case #: 1:21cv157, NOS: Abbreviated New Drug Applications (ANDA) - Property Rights, Categories: Corporations, Government, Patent
J. Farbiarz dismisses counterclaims in which a generic pharmaceutical company contends drug patents are not enforceable. The generic company is not a "small entity" as it claims, boasting growth of more than eight employees a month. Meanwhile, nothing indicates the companies may have known the original 2007 agreement would be connected to patents in the 2015 and 2016 applications.
Court: USDC New Jersey, Judge: Farbiarz , Filed On: January 11, 2024, Case #: 2:23cv18, NOS: Abbreviated New Drug Applications (ANDA) - Property Rights, Categories: Patent
J. Bumb finds for a pharmaceutical company that allegedly filed an application for a generic mifepristone product before the expiration of patent nos. 10,195,214 and 10.842,800 because plaintiff failed to demonstrate direct infringement for lack of evidence that physicians put the patented methods into use. Meanwhile, evidence did not indicate that "even a single prescription" of the patented drug had been lost to the generic alternative, and a physician would plausibly avoid infringement by faithfully following the generic drug's label.
Court: USDC New Jersey, Judge: Bumb , Filed On: December 29, 2023, Case #: 1:18cv3632, NOS: Abbreviated New Drug Applications (ANDA) - Property Rights, Categories: Patent
J. Chesler dismisses claims and counterclaims contending a competitor filed an application for a generic version of Halaven before patent no. 6,214,865 expired because the pharmaceutical company appears to demonstrate it cannot reasonably expect to continue enforcement efforts against the generic drug company, and the competitor failed to prove other companies forfeited potential market exclusivity.
Court: USDC New Jersey, Judge: Chesler , Filed On: November 7, 2023, Case #: 2:22cv5950, NOS: Abbreviated New Drug Applications (ANDA) - Property Rights, Categories: Patent
J. Connolly finds that claim 5 of U.S. Patent No. 6,911,46, which concerns an epilepsy treatment, is not invalid due to inadequate written description because drug makers seeking to market generic tablets of Briviact failed to prove a skilled artisan would obviously alter levetiracetam in such a way that it would yield a successful anti-seizure compound.
Court: USDC Delaware, Judge: Connolly, Filed On: August 16, 2023, Case #: 1:20cv987, NOS: Abbreviated New Drug Applications (ANDA) - Property Rights, Categories: Patent
[Consolidated.] J. Connolly finds that claim 13 of U.S. Patent No. RE46,284, which concerns therapy for treating colorectal cancer, is not invalid due to inadequate written descriptions. Manufacturers seeking to market a generic version of Lonsurf did not successfully argue that "common sense" would dictate administering the drug in twice-daily doses in light of clinical trials and related studies.
Court: USDC Delaware, Judge: Connolly, Filed On: August 15, 2023, Case #: 1:19cv2309, NOS: Abbreviated New Drug Applications (ANDA) - Property Rights, Categories: Patent
J. Cecchi finds that the federal patent office properly calculated the term extension for patent no. RE44,733 in claims contending competitors' drugs infringe on the patent for Bridion. The issue date of the original patent must be used for calculating an extension, not the date of the reissued patent, and congress did not intend that patentees should forfeit all rights upon reissue.
Court: USDC New Jersey, Judge: Cecchi, Filed On: June 13, 2023, Case #: 2:20cv2576, NOS: Abbreviated New Drug Applications (ANDA) - Property Rights, Categories: Civil Procedure, Patent